NDAORALTABLET
Approved
Apr 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PAMINE FORTE (methscopolamine bromide) by Sandoz is clinical pharmacology methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. First approved in 1953.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAMINE FORTE (methscopolamine bromide) is an oral anticholinergic agent approved in 1953 for gastrointestinal disorders. It reduces gastric acid secretion, inhibits GI motility, and decreases salivary excretion through blockade of parasympathetic signaling. This drug is used as adjunctive therapy in peptic ulcer disease and related acid-related conditions.
LOE Approaching
This legacy product is approaching end-of-life with minimal commercial investment; team size is likely small and focused on maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PAMINE FORTE offers limited career growth due to its LOE-approaching lifecycle and zero linked job postings. Roles available are primarily in product maintenance, legacy brand management, and compliance rather than innovation or expansion.
Regulatory Affairs Specialist
Worked on PAMINE FORTE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.